BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AeroGen, Inc. (AEGN) Announces IND Submission For Aerosolized Antibiotic


10/19/2005 5:12:06 PM

MOUNTAIN VIEW, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Aerogen, Inc. announced today that it has submitted an Investigational New Drug Application ("IND") to the U.S. Food and Drug Administration to begin a second Phase 2 study of its aerosolized antibiotic product in patients with ventilator-associated pneumonia ("VAP"). The IND is for Aerogen's proprietary drug/device combination product, which delivers a targeted dose of amikacin to the lungs of patients on mechanical ventilation. The IND contains the protocol for conduct of the Phase 2 study to be conducted in over 100 patients; this study is designed to define the effective dose of antibiotic and monitor the clinical response in patients with confirmed VAP.

"Aerogen's VAP program exemplifies our commitment to improving therapeutic options for patients in the critical care setting. We expect to initiate enrollment of this multi-center international study by the end of this year, with results targeted to be available by the third quarter of 2005," said Robert Fishman, M.D., Aerogen Vice President of Scientific Affairs.

Aerogen has completed a Phase 2 clinical study in Tours, France; results confirmed the superior efficiency of Aerogen's proprietary aerosolized technology in safely delivering amikacin to the lungs of patients on mechanical ventilation. These data were presented at the American Thoracic Society Conference in Orlando, Florida in May 2004.

Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(TM) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen currently markets the Aeroneb(R) Professional Nebulizer System for use in hospitals. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. In the U.S., Aerogen has commercialized the Aeroneb(R) Go Nebulizer for home use through its commercial partner, Evo Medical Solutions, Inc. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.

To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of the Company's control and other uncertainties, and are subject to various risk factors that could cause the Company's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in the Company's reports and other filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004 and its 424b(3) prospectus filed with the SEC on August 17, 2004. Aerogen does not undertake any obligation to update forward-looking statements.

Aerogen, Inc.

CONTACT: Dr. Jane E. Shaw, +1-650-864-7333, for Aerogen, Inc.


Read at BioSpace.com

   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->